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Abstract
Rapid diagnostic tools have been shown to improve linkage of patients to care. In the con-
text of infectious diseases, assessing the impact and cost-effectiveness of such tools at the
population level, accounting for both direct and indirect effects, is key to informing adoption
of these tools. Point-of-care (POC) CD4 testing has been shown to be highly effective in
increasing the proportion of HIV positive patients who initiate ART. We assess the impact
and cost-effectiveness of introducing POC CD4 testing at the population level in South
Africa in a range of care contexts, using a dynamic compartmental model of HIV transmis-
sion, calibrated to the South African HIV epidemic. We performed a meta-analysis to quan-
tify the differences between POC and laboratory CD4 testing on the proportion linking to
care following CD4 testing. Cumulative infections averted and incremental cost-effective-
ness ratios (ICERs) were estimated over one and three years. We estimated that POC CD4
testing introduced in the current South African care context can prevent 1.7% (95% CI:
0.4% - 4.3%) of new HIV infections over 1 year. In that context, POC CD4 testing was cost-
effective 99.8% of the time after 1 year with a median estimated ICER of US$4,468/DALY
averted. In healthcare contexts with expanded HIV testing and improved retention in care,
POC CD4 testing only became cost-effective after 3 years. The results were similar when,
in addition, ART was offered irrespective of CD4 count, and CD4 testing was used for clini-
cal assessment. Our findings suggest that even if ART is expanded to all HIV positive indi-
viduals and HIV testing efforts are increased in the near future, POC CD4 testing is a cost-
effective tool, even within a short time horizon. Our study also illustrates the importance of
evaluating the potential impact of such diagnostic technologies at the population level, so
that indirect benefits and costs can be incorporated into estimations of cost-effectiveness.
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Introduction
Antiretroviral therapy (ART) substantially improves outcomes of human immunodeficiency
virus (HIV) positive patients, particularly if initiated early [1]. But ART also dramatically
reduces the risk of onwards transmission, and thus plays a role in prevention as well as treat-
ment [2]. Following the accumulated evidence of this double benefit of ART, the World Health
Organisation (WHO) has progressively updated its guidelines for initiation of ART in individ-
uals diagnosed with HIV, gradually expanding the population for which ART initiation is rec-
ommended [3–6]. The remarkable expansion of ART availability across Sub-Saharan Africa,
where 70% of worldwide infections occur [7], has led to a drop in AIDS-related deaths, which
have decreased by 35% since peaking in 2005 [8]. In order to optimise the benefits of ART for
the individual and the population, effective administration of the treatment cascade is essential.
Improving the cascade implies early diagnosis, efficient linkage to care, timely ART initiation
in those eligible for treatment, and regular follow-up to ensure adherence and sustained viral
suppression. Yet attrition across the treatment cascade remains considerable, with only a quar-
ter of HIV positive individuals in Sub-Saharan Africa estimated to be virally suppressed in
2012 [7].
There are numerous opportunities for losses throughout the treatment cascade, in particular
when laboratory testing is involved. The latest WHO guidelines recommend immediate treat-
ment, i.e. ART initiation, in all individuals living with HIV [6]. National guidelines often, how-
ever, still contain CD4 count thresholds above which treatment is not initiated (CD4 counts
being used as a marker of immunodeficiency level). In South Africa, for example, treatment is
available only for those with low CD4 cell counts (CD4500 cells/μL), and is prioritised for
those with even lower CD4 counts (CD4350 cells/μL), severe disease and HIV/tuberculosis
co-infection [9]. Until countries adopt the most recent guidelines, CD4 testing will continue to
be carried out during treatment staging. Moreover, we anticipate that, even after immediate
treatment protocols are formally adopted, CD4 cell counts will still be measured in resource
limited settings in order to prioritise treatment for those most in need [6, 9].
In South Africa, CD4 testing facilities are generally centralised at hospital-based clinics
within large urban areas [10]. A recent review of existing services showed that more than 50
clinics providing ART are 3-4 hours drive from the closest CD4 testing facility [10]. Conse-
quently, turnaround time for a CD4 test can be a matter of weeks [10–13]. Moreover, the cur-
rent system involves the patient repeatedly visiting the clinic, at least once for a blood draw and
once to receive the CD4 test results. The time and cost (for the patient) of repeat travel to a dis-
tant clinic often leads to attrition [14, 15].
The development of point-of-care (POC) CD4 technology has been proposed as a way of
decentralising laboratory services, thereby expanding access to, and reducing turnaround time
for, CD4 testing. By delivering same day results, POC CD4 testing offers the potential for the
CD4 cell count to be assessed at the time of HIV diagnosis. By reducing the number of clinic
visits a patient is required to make, they are less likely to be lost to follow-up (LTFU) and eligi-
ble individuals may initiate treatment sooner. Several POC CD4 pilot studies have illustrated
its promise for increasing retention within the treatment cascade [12, 13, 16–18].
While POC CD4 testing has the potential to overcome the poor retention currently experi-
enced at this step within the treatment cascade, the associated costs may be high, and it is
important to assess whether this approach is cost-effective. Hyle et al. used a Monte Carlo
state-transition model to evaluate the costs and benefits of POC CD4 testing in Mozambique.
Compared to laboratory CD4 testing, it was found to be a cost-effective way to improve indi-
vidual patient outcomes in that setting [19]. This model, however, only captured the direct ben-
efits (and associated costs) of improved life expectancy to the individual, and it did not
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incorporate the indirect benefits (and costs) of reduced onwards transmission within the popu-
lation. Additionally, this paper considered only the impact of POC CD4 testing in a low income
country with a less efficient programme of linkage to care, precisely a scenario in which a bene-
fit would be expected from POC CD4 technology.
Dynamic transmission models allow capturing both direct and indirect effects of ART and
provide a suitable means by which to evaluate the potential epidemiological impact of intro-
ducing POC CD4 testing. In this study, we used mathematical modelling to evaluate the cost-
effectiveness of introducing POC CD4 testing in South Africa, compared to laboratory CD4
testing as is currently used. We considered three HIV care contexts corresponding to different
levels of HIV care delivery that may be delivered in South Africa in the near future. For each of
these, we evaluated whether the introduction of POC CD4 testing was predicted to be cost-
effective, over different time horizons. We used a probabilistic approach to assess whether our
findings were robust to uncertainties in future costs as well as in epidemiological parameters.
Methods
Epidemiological model structure
We extended a previously developed dynamic, deterministic model of heterosexual HIV trans-
mission in South Africa [20]. In brief, that model simulated a heterosexual population repre-
senting South African adults aged 15-49 years from the start of the HIV epidemic. The
population was divided by gender and sexual risk, with males additionally divided by circumci-
sion status. Births and non-HIV related mortality were included in the model. Sexual mixing
was assortative by level of risk. HIV infected individuals were classified in four CD4 count cate-
gories (in units of cells/μL: CD4 500, 350 CD4< 500, 200 CD4< 350, CD4< 200).
HIV infectivity depended on HIV disease stage and whether the individual was on ART or not;
men who were circumcised were assumed to have lower susceptibility to infection. Full details
are in Cori et al. [20].
Our extended model incorporated a more detailed HIV treatment cascade process, and was
calibrated to the most recently available HIV prevalence estimates for South Africa [21]. Spe-
cific additions were the division of the process between HIV testing and entering ART care to
include a more realistic CD4 staging step, as well as the inclusion of first line ART treatment
failure with the possibility of second line ART (see S1 Supporting Information for detail).
Once an individual tested HIV positive, they could be CD4 staged (which combines CD4
testing and receiving results). If not eligible according to national guidelines at that time, they
entered pre-ART care, otherwise they initiated ART. ART failure could occur, leading to initia-
tion on the more expensive second line ART. Individuals could be LTFU at any stage. Those
LTFU during CD4 staging re-entered the diagnostic cascade to undertake treatment at a rate
lower than that of initial entry, chosen to ensure numbers on ART were greater than 2 million
by 2012 [22]. Those LTFU while on ART could subsequently reinitiate treatment.
Model parameterisation
Basic model parameters and calibration. The epidemiological parameters were taken
from the literature where possible (see S1 Supporting Information). Model parameters antici-
pated to influence the epidemiology were varied, see Table A in S1 Supporting Information
[20]. Two million parameter sets were generated using Latin hypercube sampling with uniform
prior ranges [23]. Parameter sets which generated prevalence values within twice the UNAIDS
confidence intervals from 1993 to 2013 [21], and in which at least two million individuals were
on ART by 2012 [24, 25], were considered calibrated and used in the cost-effectiveness
analysis.
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CD4 staging parameters. To parameterise CD4 staging for both POC and laboratory
CD4 testing, we carried out a meta-analysis of clinical and observational trial data [12–14, 16–
18, 26, 27]. Not all studies reported matching data between POC and laboratory CD4 testing
arms. As such, odds ratios could not be always be computed. Instead, the proportions that suc-
cessfully received CD4 results following a CD4 test (pPOC=labCD4results) and successfully initiated ART
following receipt of CD4 results (pPOC=labARTinitiate) were individually calculated by pooling data from
the trials using a DerSimonian-Laird random effects model [28] (for further details see Table C
and S1.3.4 in S1 Supporting Information). The proportions were varied independently within
the 95% conﬁdence intervals derived in the meta-analysis.
Costs and DALYs. Following Eaton et al. [29], each compartment in the model had an
associated healthcare cost. In addition, HIV testing, CD4 testing, and end-stage care also
incurred costs. All costs were in US$ 2015. A programme markup of 1.5× was added to all
non-antiretroviral (ARV) expenditure to account for fixed costs. ARV costs were marked up
by 1.2× to account for logistics. ART costs and non-ART costs were varied (independently)
between -20% and 20% of their value (including markup) to allow for future price changes.
Economic parameters are described in S1 Supporting Information; for a list of costs used
(adjusted for inflation) see Table E in S1 Supporting Information. Disability adjusted life years
(DALYs) were calculated using standard disability weightings for HIV, see Table D in
S1 Supporting Information. All cost differences and DALYs averted in future years were dis-
counted at between 0.1% and 7.0% (varied in sensitivity analysis).
Care contexts. We assessed the potential impact and cost-effectiveness of POC CD4 test-
ing compared to laboratory testing within three distinct care contexts. These were designed to
reflect potential future HIV care contexts in the South African healthcare system. The contexts
considered were:
• Current care (CC) context: after 2015 annual HIV testing numbers continued to increase in
line with population growth (from an estimated number of HIV tests of 10 million in mid-
2011 [22]); return to ART is kept at the same level as before 2015 (a rate, varied in sensitivity
analysis, such that between 5% and 80% of those with CD4< 200 cells/μL return to ART
within one year of drop-out); no further changes in national guidelines for ART initiation.
• Enhanced counselling and testing (ECT): from 2015 the whole population tested annually
for HIV; annual rates of return from LTFU were approximately 95%; no further changes in
national guidelines for ART initiation.
• Universal test and treat (UTT): as ECT context but expansion of ART to all HIV positive
individuals; patients still received a CD4 test prior to ART initiation for clinical assessment
and, therefore, POC CD4 testing also improves linkage to care relative to laboratory CD4
testing in this context.
The first context represented a continuation of current HIV care efforts. The second assumed
extreme improvements in both HIV testing efforts and retention in care. The third further
assumed that South Africa adopted immediate treatment following the most recent WHO
guidelines [6]. The second and third contexts may seem unrealistically optimistic but together
with the first allowed us to explore the impact of POC CD4 in a wide range of care contexts.
Plan of analysis
For each of the above care contexts, two simulations were run: one with the implementation of
POC CD4 testing (from 2015 onwards) and a comparator with laboratory testing. For each
care context, the additional cost of introducing POC CD4 testing was estimated, along with the
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infections averted and DALYs averted for one and three year time horizons. A probabilistic
approach to cost-effectiveness analysis was carried out by varying the CD4 staging and eco-
nomic parameters (costs and discount rate) for each of the epidemiological parameter sets gen-
erated in calibration. Specifically, 250 CD4 and cost parameter sets were obtained by uniform
sampling within ranges shown in Table E in S1 Supporting Information and the results of the
meta-analysis, see below. Incremental cost-effectiveness ratios (ICER = cost incurred/DALYs
averted) were derived for one and three year projections for all combined parameter sets and
compared to South Africa’s GDP per capita ($6,478 [30]) to assess cost-effectiveness [31].
Ranges for the proportion of infections averted were calculated in the same way.
A sampling-based approach was used to assess sensitivity of the infections averted and
ICERs to input parameter variation [32]. Using the complete model outputs, multivariate lin-
ear regression models were constructed for both infections averted and ICERs as functions of
the varied parameters. Appropriateness of using linear models was checked by ensuring model
R2 were large. Standardised regression coefficients are reported in S2 Supporting Information,
along with the proportion of variance explained by each parameter. Since parameters are sam-
pled from a Latin hypercube, they are uncorrelated and thus the standardised regression coeffi-
cients measure one-way sensitivity (they are equal to Pearson’s correlation coefficients) [32].
The parameters which explain more than 10% of the variance are reported here, and were used
to construct linear models for ICERs and infections averted in each context, see S2 Supporting
Information.
Results
Calibration and meta-analysis
Results of the meta-analysis quantifying the differences in CD4 staging between POC and labo-
ratory CD4 testing are shown in Table 1. Prevalence and incidence over time for the three care
contexts are shown in Fig 1, for one of the 71 parameter sets that satisfied calibration require-
ments. Prevalence decreases in all three care contexts, though more rapidly in the enhanced
programmes after 2015; incidence drops rapidly after introduction of enhanced measures in
ECT and UTT contexts, after which it plateaus.
ICERs, infections averted and costs
The projections of infections averted and ICERs are shown in Fig 2 for one and three year time
horizons. The projected proportions of infections averted has a wide distribution whose width
increases over time; the median slightly decreases from one to three year projections in all con-
texts. Cost-effectiveness is higher over three years than over one year; the most cost-effective
programme is the CC context, followed by the ECT then UTT contexts.
In all three contexts, introducing POC CD4 testing led to infections averted over a one year
horizon compared to laboratory CD4 testing: 1.72% (95% confidence interval: 0.36—4.31%)
infections averted in CC context, 2.65% (0.17—8.78%) in ECT context, 3.09% (0.11—11.47%)
in UTT context. Over the same period, DALYs averted (which reflect both infections averted
Table 1. Results of meta-analysis of CD4 staging for POC CD4 and laboratory testing (95% confidence intervals shown in brackets).
Parameter Lab CD4 testing POC CD4 testing
Proportion receiving CD4 results of those CD4 tested (%) 57.7 (41.8 - 72.9) 90.8 (82.2 - 96.8)
Proportion initiating ART of those receiving CD4 results (and ART eligible) (%) 51.5 (45.1 - 57.9) 62.2 (47.5 - 75.9)
doi:10.1371/journal.pone.0158303.t001
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Fig 1. Prevalence and incidence curves. Prevalence and incidence for all three care contexts, for an arbitrarily chosen
calibrated epidemiological parameter set. For all parameter sets see Fig C in S1 Supporting Information. The colours
correspond to (from top to bottom on both panels): grey—current care (CC) context, orange—enhanced counselling and
testing (ECT), blue—universal test and treat (UTT). Also shown on the left panel are the confidence intervals of the
UNAIDS prevalence estimates (inner circles) and twice the confidence intervals (outer crosses).
doi:10.1371/journal.pone.0158303.g001
Fig 2. Violin plots showing infections averted and ICERs when introducing POC CD4 testing compared to
laboratory testing in each care context. Left plot shows infections averted across one and three year projections. The right
plot shows ICERs. The colours correspond to (from bottom to top in each year): grey—current care (CC) context, orange—
enhanced counselling and testing (ECT), blue—universal test and treat (UTT). Note: when linkage to care is high but the
effectiveness of ART in reducing infectivity is low (close to 50%), patients live longer and have more opportunity for
transmission than would be the case without the introduction of POC CD4 testing. This results in the observed negative
infections averted but, since more individuals are on treatment, DALYs averted (and so ICERs) are still positive.
doi:10.1371/journal.pone.0158303.g002
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and the improved health of those additionally on treatment) were 0.02m DALYs (0.01 million
—0.04 million DALYs) in CC context, and 0.03m DALYs (0.02 million—0.05 million DALYs)
in both ECT and UTT contexts.
After 1 year the total additional cost from introducing POC CD4 testing was $0.11 billion in
CC context, $0.22 billion in ECT context and $0.29 billion in UTT context (see Table I in S2
Supporting Information). Note each of these contexts differed greatly in total cost (with UTT
being the most expensive context) and the costs presented above represent only the additional
costs from introducing POC CD4 in each context. Results for the three year projections are
presented in S2 Supporting Information.
Cost-effectiveness analysis
Cost-effectiveness acceptability curves (CEAC) are shown in Fig 3 (for cost-effectiveness plane
graphs see Fig D in S2 Supporting Information). The CEAC curves show that introducing POC
CD4 testing into the CC context is likely to be cost-effective after one year at the willingness-
to-pay threshold of South African GDP; the ECT and UTT contexts are only likely to be cost-
effective after three years.
The probability of each of the three interventions being cost-effective after 1 year when
compared to the threshold of South Africa’s GDP per capita ($6,478 [30]) were: in the CC con-
text—99.8%, in the ECT context—34.3% and in the UTT context—1.5%. After 3 years the
probabilities of being cost-effective were: CC—100%, ECT—94.9% and UTT—84.5%. When
using a threshold of 3 times GDP per capita, introducing POC CD4 testing was cost-effective
in all three care contexts at one and three year time scales. Additional details of the results are
given in S2 Supporting Information.
Fig 3. Cost-effectiveness acceptability curves. These curves show the probability that introduction of POC
CD4 testing compared to laboratory CD4 testing is cost-effective at a range of decision rule thresholds for the
1 year projection (left) and 3 year projection (right). The colours correspond to (left to right within each plot):
grey—current care (CC) context, orange—enhanced counselling and testing (ECT), blue—universal test and
treat (UTT). The dashed line shows South African GDP per capita.
doi:10.1371/journal.pone.0158303.g003
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Sensitivity analysis
Full linear regression results for ICERs and infections averted are shown in S2 Supporting
Information, specifically Table F and Table G. Adjusted R2 values are high, demonstrating
appropriateness of the linear models. The proportion of the variance explained by each param-
eter can, therefore, be used to quantify the extent to which each parameter drove the variation
in ICERs and infections averted.
In short, the projected epidemiological impact due to the introduction of POC CD4 testing
varied due to assumptions around treatment effectiveness, and the improvement in the propor-
tion receiving their CD4 test results (and hence remaining in care) once POC CD4 testing was
introduced. In the CC context, the improvement in linkage due to the introduction of POC
CD4 testing was the key determinant of infections averted. Conversely, in the ECT and UTT
contexts, the key determinant was the reduction in infectivity when on ART, due to the large
number of individuals on ART.
Variation in ICERs was determined by several factors. In all contexts it was sensitive to the
increase in the proportion receiving their CD4 test results through the introduction of POC
CD4 testing. In terms of costs, the relative importance of ART cost and POC CD4 test cost var-
ied by time horizon and care context. In the CC context, over one and three years, the ICER
was more sensitive to costs associated with ART than with POC CD4 test costs. In ECT and
UTT contexts, the one year ICERs were largely determined by POC CD4 test costs, because of
the high volume of CD4 tests in the first year. After three years ART costs became the main
driver of ICER variation.
Discussion
In this study we have examined the epidemiological impact and cost-effectiveness of introduc-
ing point-of-care (POC) CD4 testing, in place of existing laboratory CD4 testing, in South
Africa, for three different HIV care contexts that cover the range of possible ways that HIV
care may evolve in the near future. Across all contexts considered, POC CD4 testing results in
1.7-3.1% of new HIV infections averted during the first year. After one year in the current care
(CC) context, which most closely represents the current care situation in South Africa, the
introduction of POC CD4 testing has a 99.8% probability of being cost-effective compared to
the threshold of South African GDP per capita ($6,478), with a median ICER of $4,468/DALY
averted. Cost-effectiveness increases over time, so that the probability it is cost-effective is
100% after three years. In the two care contexts with more intensive HIV testing and linkage to
care (enhanced counselling and testing (ECT) and universal test and treat (UTT)), the median
ICER over the first year is $6,986/DALY averted and $9,215/DALY averted respectively, and
introducing POC CD4 testing is unlikely to be cost-effective over one year at the threshold of
South African GDP per capita. In both contexts, however, the probability that the intervention
is cost-effective (given the willingness-to-pay threshold of South African per-capita GDP) is
higher in the three year than in the one year scenario: within three years the probability of
being cost-effective is 84.5% in the UTT context, and higher in the intermediate (ECT) context.
Given the past delays in adopting and implementing changes in WHO guidelines, and the
financial and infrastructural challenges associated with moving to ART irrespective of CD4
count in a country with such high prevalence, the CC context is likely to remain the most rep-
resentative context in the short term. In that context POC CD4 testing was found to be cost-
effective even over a one year horizon. Anticipated expansions in treatment and testing may
make the ECT and UTT contexts more representative of future HIV care in South Africa. Our
results show that the introduction of POC CD4 testing is very likely to be cost-effective over
three years in these contexts.
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Hyle et al. [19] previously found that introducing POC CD4 testing was cost-effective in the
context of the HIV epidemic in Mozambique, with the threshold for ART initiation at CD4<
250 cells/μL, with an ICER of $500 per year of life saved. They found that POC CD4 testing
was no longer cost-effective in that setting when linkage to care was improved. This is consis-
tent with our finding that cost-effectiveness is notably lower in the ECT and UTT contexts, in
which numbers HIV testing was significantly increased compared to the CC context. This con-
cordance in findings is notable given differences between the studies: our analysis considers
shorter time horizons than Hyle et al., incorporates indirect effects and is set within a higher
income setting.
The results demonstrate that POC CD4 testing is more likely to be cost-effective when intro-
duced into less comprehensive HIV care contexts: firstly, the probability of being cost-effective
is higher in the current care context compared to the enhanced (ECT and UTT) contexts, in
which additional HIV testing occurs and retention in care is improved. Secondly, cost-effec-
tiveness increases (the ICER decreases) when the improvement in proportion receiving their
results (in the POC versus laboratory CD4 testing strategy) is increased. This may occur in situ-
ations where the proportion successfully CD4 staging with laboratory testing is particularly
low.
This supports a more targeted approach to its introduction. Glencross et al. recently
reviewed the provision of CD4 services at a subnational level across South Africa [10], identify-
ing gaps in service provision in remote areas. They proposed an integrated tiered service deliv-
ery model that allows an extension of services to rural areas while making use of existing clinic
infrastructure. A combination of POC CD4 testing and decentralised laboratory tiers was
found to be a cheaper way to expand diagnostic capacity as opposed to offering widespread
POC CD4 testing [10]. Prioritising implementation to specific settings could further reduce
costs through hierarchical support across tiers, for example through increased efficiency of
training and quality control.
One strength of this study is the use of a dynamic transmission model, which captures the
prevention of future HIV infections through reduced prevalence and the associated future
healthcare savings. This approach could be used in future work to estimate the population-
level impact of POC CD4 testing in other settings, especially those with less efficient linkage to
care. Another strength is that a previous iteration of the model was part of a model comparison
exercise in which the projected reduction in HIV incidence in South Africa due to an ART
intervention was, at least in the short-term, consistent with other mathematical models [33]. In
addition, our model is fitted to, and reproduces, the most recent UNAIDS HIV prevalence
trends for South Africa. A difficulty in parameterising the model was the lack of data concern-
ing re-entry into care after ART drop-out. To circumvent this issue, we fully explored the
uncertainty in our analysis and found that it did not influence the outcomes within our time-
frame. Moreover, our use of short timeframes ensures we are confident that our findings are
robust, since the use of short term incidence measures in modelling studies has been shown to
be very robust to changes in model structure [33]. Finally, quantifying the impact of CD4 test-
ing on linkage to care was a key part of the parameterisation and was achieved by a meta-
analysis.
Conclusions
This study shows that in the middle-income setting of South Africa, introduction of POC CD4
testing is likely to be cost-effective (under the threshold of GDP per capita), in comparison to
existing laboratory CD4 testing, and that cost-effectiveness increases over time. CD4 counts
may stop being used to assess eligibility for ART initiation in South Africa within the next
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couple of years; however, we found that the introduction of POC CD4 testing in the current
care context was very likely to be cost-effective within one year. Moreover, CD4 testing is likely
to remain a widespread tool for clinical staging of HIV positive patients before ART initiation.
Given this, our findings suggest that even if ART is expanded to all HIV positive individuals in
the near future, and HIV testing efforts are substantially increased, POC CD4 testing is still a
cost-effective tool. Our study also illustrates the wider importance of evaluating the potential
impact and cost-effectiveness of such diagnostic technologies at the population level in the
future.
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